Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer

Pugliano, Lina; Azambuja, Evandro de

doi:10.1159/000342209

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on single agent gemcitabine in anthracycline and taxane pre-treated patients suggest an overall response rate ranging from 12% to 30%, but with significant haematological toxicity 10, where more favourable results have been observed in combination with taxanes 22-24. Among vinca alkaloids, vinorelbine is widely employed in pretreated breast cancer, in anthracycline and taxane pretreated patients yielding response rates ranging from 10% to 35%, depending on the amount of the pre-treatment 25. It is usually well tolerated, but it is frequently employed in combination regimens, and no evidence of survival benefit from randomized trials are reported 26-28.…”

Section: Discussionmentioning

confidence: 99%

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Gamucci¹,

Michelotti²,

Pizzuti³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease.Objectives: This multicenter observational retrospective study was performed in order to evaluate activity and tolerability of eribulin in real-world patient population.Methods: 133 advanced breast cancer patients pretreated with ≥ 2 chemotherapy lines for metastatic disease were retrospectively enrolled in the observational trial in 11 italian cancer centres.Results: A median of 5 cycles of eribulin (range, 1-15) were administered. Twenty-eight partial responses were observed, for an overall response rate of 21.1% (95%CI,14.1-28.0). A stable disease was recorded in 57 patients (42.8%), and a clinical benefit (response or stable disease lasting ≥ six months) was observed in 51 patients (38.3%, 95%CI, 30.1-46.6). The subgroup analysis showed that a significant improvement in term of partial response and clinical benefit was achieved when eribulin was administered in HER-2 negative tumors (p=0.01 and p=0.004, respectively) and when it is given as third-line (p=0.09 and p=0.02, respectively). Toxicity was manageable; fatigue is the most common side effect observed, usually of low-grade, and clearly cumulative-dose related.Conclusions: In this retrospective, observational analysis eribulin confirmed its efficacy and manageable tolerability even in real-world population and in heavily pretreated patients.

show abstract